{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:31:49Z","timestamp":1783629109752,"version":"3.55.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Feminizing and masculinizing hormone treatments are established components of management in transgender patients. Exogenous hormones have been associated with hemostatic effects, which are well-studied in cis-gender individuals on hormone replacement therapy (HRT). Unfortunately, comprehensive understanding of their effects on venous thromboembolism (VTE) risk in the transgender population is lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>This manuscript aims to identify the risk of VTE among transgender individuals undergoing cross-sex hormone therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Systematic review of the literature was performed in March 2020 for studies reporting VTE rates in transgender patients undergoing hormone treatment and rates in cis-gender patients on HRT. Data regarding demographics, hormone therapy, and VTE incidence were collected and pooled for analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome<\/jats:title><jats:p>The primary outcome of interest was the development of a VTE event in association with concurrent hormone administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Overall, 22 studies were included with 11 reporting VTE rates among transgender patients, 6 in cis-female patients, and 5 in cis-male patients. Data from 9,180 transgender patients (6,068 assigned male at birth [AMAB] and 3,112 assigned female at birth [AFAB]) undergoing hormone treatment and 103,713 cis-gender patients (18,748 female and 84,965 male) undergoing HRT were pooled. The incidence of VTE was higher in AMAB patients compared to AFAB patients (42.8 vs 10.8 VTE per 10,000 patient years; P = .02). The rate of VTE incidences in AMAB patients appears similar or higher than the rate demonstrated in cis-females on HRT. VTE incidence in AFAB patients, however, is similar to the published rates in cis-males on HRT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Implications<\/jats:title><jats:p>AMAB patients on hormone therapy have higher VTE rates than AFAB patients. AMAB and AFAB patients may have similar VTE incidence to cis-female and cis-male patients on hormone replacement therapy, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Strengths &amp; Limitations<\/jats:title><jats:p>This is the first study to aggregate and quantify the development of VTE events in association with hormone therapy in transgender patients. It places these values in the context of rates published in more widely studied populations. It is limited by its retrospective data and heterogenic data.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Surgical planning regarding perioperative and postoperative VTE prophylaxis or cessation of hormone therapy should take into account each patient\u2019s Caprini risk assessment and the nature of each intervention.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.jsxm.2021.04.006","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T04:27:24Z","timestamp":1623817644000},"page":"1280-1291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Risk for Venous Thromboembolism in Transgender Patients Undergoing Cross-Sex Hormone Treatment: A Systematic Review"],"prefix":"10.1093","volume":"18","author":[{"given":"Vasanth S.","family":"Kotamarti","sequence":"first","affiliation":[{"name":"Division of Plastic Surgery, Albany Medical Center , Albany, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Greige","sequence":"additional","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Department of Surgery, Montefiore Medical Center , Bronx, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adee J.","family":"Heiman","sequence":"additional","affiliation":[{"name":"Division of Plastic Surgery, Albany Medical Center , Albany, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashit","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Plastic Surgery, Albany Medical Center , Albany, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Ricci","sequence":"additional","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Department of Surgery, Montefiore Medical Center , Bronx, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0140-6736(16)00683-8","article-title":"Transgender people: health at the margins of society","volume":"388","author":"Winter","year":"2016","journal-title":"Lancet"},{"key":"2023041407033361500_","first-page":"S229","volume":"80","author":"Tran","year":"2018","journal-title":"Gender affirmation surgery: A synopsis using american college of surgeons national surgery quality improvement program and national inpatient sample databases"},{"key":"2023041407033361500_","first-page":"165","volume":"13","author":"Coleman","year":"2012","journal-title":"Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7"},{"key":"2023041407033361500_","first-page":"319","volume":"5","author":"Nakatsuka","year":"2010","journal-title":"Metabolism. Endocrine treatment of transsexuals: Assessment of cardiovascular risk factors"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061609","article-title":"Hormonal treatment strategies tailored to non-binary transgender individuals","volume":"9","author":"Cocchetti","year":"2020","journal-title":"J Clin Med"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-8587(16)30319-9","article-title":"Oestrogen and anti-androgen therapy for transgender women","volume":"5","author":"Tangpricha","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/GME.0000000000001232","article-title":"Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy","volume":"25","author":"Laliberte","year":"2018","journal-title":"Menopause"},{"key":"2023041407033361500_","first-page":"1227","volume":"336","author":"Canonico","year":"2008","journal-title":"Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0038-1646283","article-title":"Coagulation activation following estrogen administration to postmenopausal women","volume":"68","author":"Caine","year":"1992","journal-title":"Thromb Haemost"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002229.pub3","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women","author":"Main","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1631\/jzus.B1000106","article-title":"Risk of venous thromboembolic disease in postmenopausal women taking oral or transdermal hormone replacement therapy","volume":"12","author":"Ruszkowska","year":"2011","journal-title":"J Zhejiang Univ Sci B"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/j.1538-7836.2012.04919.x","article-title":"Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study","volume":"10","author":"Sweetland","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"4 Pt 1","key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.juro.2015.10.134","article-title":"Association between use of exogenous testosterone therapy and risk of venous thrombotic events among exogenous testosterone treated and untreated men with hypogonadism","volume":"195","author":"Li","year":"2016","journal-title":"J Urol"},{"key":"2023041407033361500_","first-page":"881","volume":"5","author":"Velho","year":"2017","journal-title":"Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: A systematic review"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","DOI":"10.1177\/2048004019880745","article-title":"Cardiovascular disease in transgendered people: a review of the literature and discussion of risk","author":"Seal","year":"2019","journal-title":"JRSM Cardiovasc Dis"},{"key":"2023041407033361500_","first-page":"10209","article-title":"Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy","author":"Goldstein","year":"2019","journal-title":"J Blood Med"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1161\/HYPERTENSIONAHA.119.13080","article-title":"Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults","volume":"74","author":"Connelly","year":"2019","journal-title":"Hypertension"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/and.12150","article-title":"Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review","volume":"46","author":"Asscheman","year":"2014","journal-title":"Andrologia"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jsxm.2016.09.001","article-title":"Incidence of venous thromboembolism in transgender women receiving oral estradiol","volume":"13","author":"Arnold","year":"2016","journal-title":"J Sex Med"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0026-0495(89)90233-3","article-title":"Mortality and morbidity in transsexual patients with cross-gender hormone treatment","volume":"38","author":"Asscheman","year":"1989","journal-title":"Metabolism"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-2005-865900","article-title":"Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist","volume":"113","author":"Dittrich","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2023041407033361500_","first-page":"17136","author":"Getahun","year":"2018","journal-title":"Acute cardiovascular events in transgender patients"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4158\/EP12170.OR","article-title":"Endocrine treatment of transsexual persons: Extensive personal experience","volume":"19","author":"Leinung","year":"2013","journal-title":"Endocr Pract"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.fertnstert.2008.12.017","article-title":"Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy","volume":"93","author":"Ott","year":"2010","journal-title":"Fertil Steril"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1210\/jc.2012-2030","article-title":"Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens","volume":"97","author":"Seal","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2265.1997.2601068.x","article-title":"Mortality and morbidity in transsexual subjects treated with cross-sex hormones","volume":"47","author":"van Kesteren","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023041407033361500_","first-page":"32969","article-title":"Cross-sex hormone therapy related adverse events: Data from a large gender identity unit","author":"Wierckx","year":"2013","journal-title":"Endocrine Abstracts"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1111\/j.1743-6109.2012.02876.x","article-title":"Long-Term evaluation of cross-sex hormone treatment in transsexual persons","volume":"9","author":"Wierckx","year":"2012","journal-title":"Journal of Sexual Medicine"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/CIRCULATIONAHA.118.038584","article-title":"Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy","volume":"139","author":"Nota","year":"2019","journal-title":"Circulation"},{"key":"2023041407033361500_","article-title":"Long-term hormone therapy for perimenopausal and postmenopausal women","volume":"1","author":"Marjoribanks","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bju.14149","article-title":"Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men","volume":"121","author":"Cole","year":"2018","journal-title":"BJU Int"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archinte.166.7.772","article-title":"Venous thrombosis and conjugated equine estrogen in women without a uterus","volume":"166","author":"Curb","year":"2006","journal-title":"Arch Intern Med"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1505241","article-title":"Vascular effects of early versus late postmenopausal treatment with estradiol","volume":"374","author":"Hodis","year":"2016","journal-title":"N Engl J Med"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"939","DOI":"10.7326\/0003-4819-135-11-200112040-00005","article-title":"Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial","volume":"135","author":"Hodis","year":"2001","journal-title":"Ann Intern Med"},{"key":"2023041407033361500_","first-page":"124127","article-title":"Medical treatments for hypogonadism do not significantly increase the risk of deep vein thrombosis over general population risk","author":"Kavoussi","year":"2019","journal-title":"Urology"},{"key":"2023041407033361500_","first-page":"355i5968","article-title":"Testosterone treatment and risk of venous thromboembolism: Population based case-control study","author":"Martinez","year":"2016","journal-title":"BMJ"},{"issue":"4 Suppl","key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"54s","DOI":"10.1016\/0197-2456(94)00113-H","article-title":"Baseline characteristics of the PEPI participants. Postmenopausal estrogen\/progestin interventions","volume":"16","author":"Miller","year":"1995","journal-title":"Control Clin Trials"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.urology.2015.03.049","article-title":"Association between testosterone supplementation therapy and thrombotic events in elderly men","volume":"86","author":"Ramasamy","year":"2015","journal-title":"Urology"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.chest.2016.05.007","article-title":"Association between testosterone replacement therapy and the incidence of DVT and pulmonary embolism: A retrospective cohort study of the veterans administration database","volume":"150","author":"Sharma","year":"2016","journal-title":"Chest"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/bmj.39266.425069.AD","article-title":"Main morbidities recorded in the women\u2019s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women","volume":"335","author":"Vickers","year":"2007","journal-title":"BMJ"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1024\/0301-1526\/a000726","article-title":"Sex hormones and venous thromboembolism - from contraception to hormone replacement therapy","volume":"47","author":"Beyer-Westendorf","year":"2018","journal-title":"Vasa"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.24593","article-title":"Thrombotic issues in transgender medicine: A review","volume":"92","author":"Shatzel","year":"2017","journal-title":"Am J Hematol"},{"key":"2023041407033361500_","first-page":"5723","volume":"88","author":"Toorians","year":"2003","journal-title":"Endocrine care-of special interest to the practice of endocrinology-venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.beem.2012.09.004","article-title":"Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills","volume":"27","author":"Sitruk-Ware","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2023041407033361500_","article-title":"Effect of cross-sex hormone therapy on venous thromboembolism risk in male-to-female gender-affirming surgery","author":"Haveles","year":"2020","journal-title":"Ann Plast Surg"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamasurg.2018.4598","article-title":"Association of surgical risk with exogenous hormone use in transgender patients: A systematic review","volume":"154","author":"Boskey","year":"2019","journal-title":"JAMA Surg"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"1081e","DOI":"10.1097\/PRS.0000000000005595","article-title":"Current concepts in feminizing gender surgery","volume":"143","author":"Safa","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"857e","DOI":"10.1097\/PRS.0000000000005453","article-title":"Current concepts in masculinizing gender surgery","volume":"143","author":"Safa","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1210\/jc.2013-1970","article-title":"Beneficial and adverse effects of testosterone on the cardiovascular system in men","volume":"98","author":"Ruige","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041407033361500_","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9610(00)00331-7","article-title":"Estrogen replacement therapy and the surgeon","volume":"179","author":"Shackelford","year":"2000","journal-title":"Am J Surg"},{"issue":"9 Suppl","key":"2023041407033361500_","article-title":"Transgender subcutaneous mastectomy for gender affirmation: A single surgeon\u2019s 5-year experience","volume":"4","author":"Cameron","year":"2016","journal-title":"Plast Reconstr Surg Glob Open"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360952100429X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360952100429X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/18\/7\/1280\/49887521\/jsm_18_7_1280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/18\/7\/1280\/49887521\/jsm_18_7_1280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T23:05:18Z","timestamp":1699139118000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/18\/7\/1280\/6956102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,6,14]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2021.04.006","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk for Venous Thromboembolism in Transgender Patients Undergoing Cross-Sex Hormone Treatment: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2021.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021, International Society of Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}